Alan B. Lancz & Associates, Inc. Abb Vie Inc. Transaction History
Alan B. Lancz & Associates, Inc.
- $94.4 Million
- Q4 2023
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 6,167 shares of ABBV stock, worth $1.05 Million. This represents 1.01% of its overall portfolio holdings.
Number of Shares
6,167
Previous 6,167
-0.0%
Holding current value
$1.05 Million
Previous $919,000
3.92%
% of portfolio
1.01%
Previous 1.05%
Shares
4 transactions
Others Institutions Holding ABBV
# of Institutions
3,657Shares Held
1.24BCall Options Held
15.5MPut Options Held
11.6M-
Vanguard Group Inc Valley Forge, PA170MShares$29 Billion0.62% of portfolio
-
Black Rock Inc. New York, NY143MShares$24.3 Billion0.61% of portfolio
-
State Street Corp Boston, MA78MShares$13.3 Billion0.64% of portfolio
-
Jpmorgan Chase & CO New York, NY51.3MShares$8.73 Billion0.85% of portfolio
-
Capital International Investors Los Angeles, CA48.1MShares$8.19 Billion1.81% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $301B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...